To the Moon
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please help by putting in symbol requests to Stockcharts.com for $TMSH by visiting the following link http://stockcharts.com/support/symbolrequest.html
I Don't think $TMSH will be pulling back to the .002's again! Looking for higher highs and higher lows this week like the last couple weeks!
It would be beneficial to get on there even if its only at night! Help us shareholders communicate with eachother...
Do you have Skype? If not get on there and hit me with a request to StockSumo. I will create a $TMSH chatboard for instant messaging so shareholders can communicate with one another!
Excellent $TMSH DD, now lets see some ask slappage and some uptick action!!!
Back on my radar, saw that $TMSH buzz growing on Twitter! Interesting activity going on in the stock this week. Definately being accumulated, looking for it to continue its uptrend off of a bottom. Float is so tight on this, $TMSH could really take off!
$ROTH .006x .0065 gearing up to break nhod into the close!
$ROTH +9% .0064 up
$ROTH Big bids in at .0056 offers just got lifted at .006 time to move back up!!!
Absolutely I agree 100%... One of my favorite terms is "Buy it while its silent and sell the sizzle" another good one is "Buy it while its Quiet sell the Riot" either way IMO now is the time to be accumulating $ROTH on this consolidation... Long $ROTH and still a believer.
Regards,
Sumo
$ROTH +4% .0055x .006 offer just got lifted at .0055 and some nice sized bids are sitting there... Green is good...
Thats correct, and so far $ROTH has offered up a few chances at making some nice profits over the last year! There has been dips and rips, savvy traders like you and I who accumulate the pullbacks and sell into the rallies are making bank! Thats all that counts. Lookin forward to continuing to make money of this stock...
$ROTH Bottom is back in time to move back up!
What Firm? Can you give links to support?
$ROTH Oversold great buying opp on this dip...
Seriously frontloaded yesterday? The stock didn't even trade a million shares... ASCM Is shorting right here watch it rebound...
Thanks for heads up, I've been on this board for months. I don't believe this is a one day wonder promo. From my experience this looks like a push to establish higher highs and support a higher base. Lets go $ROTH
News from $ROTH just out! PharmaRoth Labs, Inc. Provides Update on Registration Process to Market and Distribute Sucanon in India
https://finance.yahoo.com/news/pharmaroth-labs-inc-provides-registration-133000137.html
LAS VEGAS, NV -- (Marketwired) -- 02/23/16 -- PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to provide this update regarding the registration process in India. The Company previously announced the execution of a Distribution Agreement under which Sucanon® would be marketed and distributed as an Over the Counter (OTC). The Ministry of Health in India has approved all of the labeling and marketing information for the product container, allowing Sucanon®'s application to move forward to the clinical trial phase.
"We are very pleased with how smoothly the registration process has been going in India," commented Luis Lopez, CEO of PharmaRoth. "The Ministry's approval of the artwork design on the packaging allows us to move on to the next significant milestone: to submit the completed application for the registration and begin the 12-week clinical trial, which we plan to start soon."
India, by the nature of its immense population and the rate of Type-II Diabetes growth, is a very important market for PharmaRoth. According to the Australian Medical Journal, in the year 2000, India had the highest number of people afflicted with Type-II Diabetes; and according to predictions, up to 79.4 million people in India may be afflicted with diabetes mellitus by the year 2030.
"Our company has the ability to offer an effective OTC Type-II diabetes treatment with no side effects to a region of world where the disease is rampant, and we are proud to be able to provide Sucanon® to the people of India," Mr. Lopez concluded.
About Sucanon® Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.
For more information regarding Sucanon®, please visit www.pharmaroth.com
About PharmaRoth PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
For Investor Relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
mike@parvise.com
News from $ROTH just out! PharmaRoth Labs, Inc. Provides Update on Registration Process to Market and Distribute Sucanon in India
https://finance.yahoo.com/news/pharmaroth-labs-inc-provides-registration-133000137.html
LAS VEGAS, NV -- (Marketwired) -- 02/23/16 -- PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to provide this update regarding the registration process in India. The Company previously announced the execution of a Distribution Agreement under which Sucanon® would be marketed and distributed as an Over the Counter (OTC). The Ministry of Health in India has approved all of the labeling and marketing information for the product container, allowing Sucanon®'s application to move forward to the clinical trial phase.
"We are very pleased with how smoothly the registration process has been going in India," commented Luis Lopez, CEO of PharmaRoth. "The Ministry's approval of the artwork design on the packaging allows us to move on to the next significant milestone: to submit the completed application for the registration and begin the 12-week clinical trial, which we plan to start soon."
India, by the nature of its immense population and the rate of Type-II Diabetes growth, is a very important market for PharmaRoth. According to the Australian Medical Journal, in the year 2000, India had the highest number of people afflicted with Type-II Diabetes; and according to predictions, up to 79.4 million people in India may be afflicted with diabetes mellitus by the year 2030.
"Our company has the ability to offer an effective OTC Type-II diabetes treatment with no side effects to a region of world where the disease is rampant, and we are proud to be able to provide Sucanon® to the people of India," Mr. Lopez concluded.
About Sucanon® Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.
For more information regarding Sucanon®, please visit www.pharmaroth.com
About PharmaRoth PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
For Investor Relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
mike@parvise.com
Looking for a solid move out of $ROTH today!
$ROTH News
PharmaRoth Labs, Inc. Provides Update on Registration Process to Market and Distribute Sucanon in India
LAS VEGAS, NV -- (Marketwired) -- 02/23/16 -- PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to provide this update regarding the registration process in India. The Company previously announced the execution of a Distribution Agreement under which Sucanon® would be marketed and distributed as an Over the Counter (OTC). The Ministry of Health in India has approved all of the labeling and marketing information for the product container, allowing Sucanon®'s application to move forward to the clinical trial phase.
"We are very pleased with how smoothly the registration process has been going in India," commented Luis Lopez, CEO of PharmaRoth. "The Ministry's approval of the artwork design on the packaging allows us to move on to the next significant milestone: to submit the completed application for the registration and begin the 12-week clinical trial, which we plan to start soon."
India, by the nature of its immense population and the rate of Type-II Diabetes growth, is a very important market for PharmaRoth. According to the Australian Medical Journal, in the year 2000, India had the highest number of people afflicted with Type-II Diabetes; and according to predictions, up to 79.4 million people in India may be afflicted with diabetes mellitus by the year 2030.
"Our company has the ability to offer an effective OTC Type-II diabetes treatment with no side effects to a region of world where the disease is rampant, and we are proud to be able to provide Sucanon® to the people of India," Mr. Lopez concluded.
About Sucanon® Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.
For more information regarding Sucanon®, please visit www.pharmaroth.com
About PharmaRoth PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
For Investor Relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
mike@parvise.com
$PSID Appearing at the SeeThruEquity Conference today!!!
CEO, William J. Caragol, will present at the SeeThruEquity Second Annual Innovations Investor Conference in Miami, FL, on Monday, February 22, 2016, at the Ritz Carlton on South Beach.
Mr. Caragol will provide an update on PositiveID’s Firefly Dx real-time pathogen detection system, as well as an overview of the Company’s recent acquisitions of Thermomedics, which markets the FDA-cleared, non-contact Caregiver® thermometer, and E-N-G Mobile Systems, Inc. (“ENG”), a leader in mobile labs, homeland security and communications vehicles.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations.
Michael James Enterprises Skin Care Formulator Delivers First Draft of Acne Kit To Ivy League Institution And Receives Formulation Approval
Facebook Page Goes Live
SHORT HILLS, N.J., Feb. 17, 2016 /PRNewswire/ -- Michael James Enterprises, Inc. (OTC: MJTV), delivered the first set of samples of its 4 product acne kit to the creator of the patented technology at the renowned Ivy League institution and received confirmation that the formulations are properly combined. MJTV also went live with its Facebook page which can be viewed by going to the following link www.facebook.com/MJTV.Inc
Konstantinos M. Lahanas, Ph.D, of The Lahanas Group reported that the next step in the formulation process is to add in aromas and resubmit for final approval prior to moving onto the next steps.
Michael James Enterprises CEO James M. Farinella stated, "Reaching the milestone of an approved formulation from our patent holder is a very significant achievement for MJTV. The team set out to develop a disruptive product offering and we are now ready to prove we did so."
The next step after final approval is to choose industry-leading companies to begin independent third party benchmarking. This process includes elective lab testing, comparative use studies against leading competitors and before and after pictures.
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.
CONTACT INFORMATION:
Michael James Enterprises, Inc.
784 Morris Turnpike, Suite #334
Short Hills, NJ
07078 Tel Tele 908-204-0004
Thats right, these are trading vehicles. Not something to get married to, buy supports and take profits at resistance. $ROTH held support above the moving averages and looks ready to break prior resistance and test new highs. So with that said this looks like a buy on dips... I'm holding for the next leg up!
$PSID FEATURED IN: WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
WVC Article: http://goo.gl/k708hV
Companies Mentioned: $INO, $CMRX, $BCRX, $XON
$PSID going to be trial testing for the Zika Virus! https://www.genomeweb.com/pcr/genarraytion-launches-test-mosquito-borne-pathogens-amidst-new-cdc-zika-testing-guidelines “The firm is also developing molecular assays for PositiveID. ‘They have successfully tested many of our assays on their breadboard platform [and] GenArraytion will be shipping them a Zika assay for testing this month,’ he said.”
$PSID going to be trial testing for the Zika Virus! https://www.genomeweb.com/pcr/genarraytion-launches-test-mosquito-borne-pathogens-amidst-new-cdc-zika-testing-guidelines “The firm is also developing molecular assays for PositiveID. ‘They have successfully tested many of our assays on their breadboard platform [and] GenArraytion will be shipping them a Zika assay for testing this month,’ he said.”